


BCX-1898

Cat. No.:	HY-105395
CAS No.:	345267-14-3
Molecular Formula:	C ₁₇ H ₃₂ N ₄ O ₃
Molecular Weight:	340.46
Target:	Influenza Virus
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BCX-1898, a cyclopentane derivative, is an orally active and selective influenza virus neuraminidase inhibitor. BCX-1898 has antiviral activity with EC ₅₀ s of <0.01-21 μM on influenza A (H1N1, H3N2, and H5N1) and influenza B viruses replication in MDCK cells. BCX-1898 shows protection against the mouse influenza model ^{[1][2]} .								
In Vivo	<p>BCX-1898 (1, 10 mg/kg/day; Oral; 22 days) shows complete protection against the influenza virus with 10 mg/kg/day^[2]. BCX-1898 (0.01, 0.1 mg/kg/day; intranasal treatment; 20 days) demonstrates complete protection (10 out of 10 survived)^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Mice (13-18 g) infected with the A/Turkey/Mas/ 76 X A/Beijing/32/92 (H6N2) influenza virus^[2]</td> </tr> <tr> <td>Dosage:</td> <td>1, 10 mg/kg/day</td> </tr> <tr> <td>Administration:</td> <td>Oral; 22 days</td> </tr> <tr> <td>Result:</td> <td>Showed complete protection against the influenza virus with 10 mg/kg/day, whereas at dose level (1 mg/kg/day) showed only a 10% protection against the influenza virus.</td> </tr> </table>	Animal Model:	Mice (13-18 g) infected with the A/Turkey/Mas/ 76 X A/Beijing/32/92 (H6N2) influenza virus ^[2]	Dosage:	1, 10 mg/kg/day	Administration:	Oral; 22 days	Result:	Showed complete protection against the influenza virus with 10 mg/kg/day, whereas at dose level (1 mg/kg/day) showed only a 10% protection against the influenza virus.
Animal Model:	Mice (13-18 g) infected with the A/Turkey/Mas/ 76 X A/Beijing/32/92 (H6N2) influenza virus ^[2]								
Dosage:	1, 10 mg/kg/day								
Administration:	Oral; 22 days								
Result:	Showed complete protection against the influenza virus with 10 mg/kg/day, whereas at dose level (1 mg/kg/day) showed only a 10% protection against the influenza virus.								

REFERENCES

- [1]. D F Smee, et al. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. *Antimicrob Agents Chemother.* 2001 Mar;45(3):743-8.
- [2]. Pooran Chand, et al. Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo. *Bioorg Med Chem.* 2005 Jun 2;13(12):4071-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA